Melanotan I vs Melanotan II

Evidence-based comparison · Updated 2026

Summary

Melanotan I (afamelanotide) is the clinically validated choice for photoprotection and erythropoietic protoporphyria, backed by FDA approval and a selective MC1R mechanism with a favorable safety profile. Melanotan II is a research-only compound with broader receptor activity that also affects libido and appetite alongside tanning. Choose Melanotan I for a regulated, medically recognized application; consider Melanotan II only in a controlled research context.

Side-by-Side Comparison

	Melanotan I	Melanotan II
Evidence	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data
Regulatory	FDA ApprovedFDA ApprovedApproved by the US Food and Drug Administration for at least one indication	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Benefits	+Induces skin pigmentation and tanning +Provides photoprotection against UV damage +Reduces photosensitivity in erythropoietic protoporphyria +Melanocortin receptor agonist activity +Fewer systemic side effects than Melanotan II	+Stimulates melanogenesis (tanning) +Tanning without UV exposure (photoprotection) +Appetite suppression +Libido enhancement +May reduce sun damage risk
Dosage	0.5-1 mg — 1x daily	250-500 mcg mcg — Daily until desired tan, then 2-3x/week maintenance
Route	Subcutaneous	Subcutaneous
Category	Tanning & Pigmentation	Tanning & Pigmentation

Full research page

Melanotan I →

Full research page

Melanotan II →

Which Should You Choose?

Melanotan I selectively targets MC1R to drive eumelanin synthesis with minimal off-target activity, while Melanotan II activates multiple melanocortin receptor subtypes, producing tanning alongside systemic effects on sexual function and appetite regulation.

Choose Melanotan I when:

+You require a clinically approved, well-characterized compound for legitimate photoprotection or EPP management under physician supervision.
+You prioritize a selective MC1R mechanism that minimizes systemic side effects such as nausea, spontaneous erection, or cardiovascular changes.
+You need a peptide with Grade A evidence and a documented long-term safety profile from controlled human trials.

Choose Melanotan II when:

+The research objective specifically requires simultaneous investigation of melanogenesis alongside melanocortin-driven effects on libido or appetite in a preclinical or approved research setting.
+The study design calls for tanning induction without any UV exposure component, and the broader receptor activity profile is acceptable within the protocol.
+You are conducting exploratory research into multi-receptor melanocortin pharmacology where off-target MC3R and MC4R engagement is a relevant variable.

Stacking Melanotan I and Melanotan II is not an established or documented research practice, as both compounds target overlapping MC1R pathways, offering no additive mechanistic rationale while compounding the risk of adverse effects.

Frequently Asked Questions

Do Melanotan I and Melanotan II produce the same quality of tanning response, or does one produce deeper or longer-lasting pigmentation?⌄

Both peptides increase eumelanin synthesis via MC1R activation, but clinical data on Melanotan I consistently demonstrate sustained, dose-dependent pigmentation in EPP patients with repeat implant cycles. Melanotan II produces rapid tanning in research contexts, though comparative controlled trials against afamelanotide are absent. The pigmentation quality from Melanotan I is considered more predictable given its selective mechanism, whereas Melanotan II responses are less systematically characterized across populations.

How do the side effect profiles of Melanotan I and Melanotan II differ when choosing between them for a research protocol?⌄

Melanotan I's selective MC1R binding largely confines side effects to transient nausea and injection-site reactions, with no documented effects on sexual function or appetite at therapeutic doses. Melanotan II's activity at MC3R and MC4R introduces a substantially different side effect burden, including spontaneous erections, nausea, facial flushing, and appetite suppression. For protocols where off-target systemic effects would confound results or pose subject safety concerns, Melanotan I presents a considerably cleaner pharmacological profile.

Is the timeline to visible pigmentation different between Melanotan I and Melanotan II?⌄

Melanotan II is generally reported to produce visible tanning within days of initial dosing in research subjects, reflecting its rapid receptor activation across multiple tissue types. Melanotan I administered as a subcutaneous implant (Scenesse) typically produces measurable pigmentation increases within two weeks, with clinical protection benefits assessed over a 60-day implant cycle. The faster onset observed with Melanotan II may reflect broader receptor engagement and higher circulating peptide levels rather than superior MC1R potency.

Can Melanotan I be substituted for Melanotan II in existing research designs that used Melanotan II, and would the data be comparable?⌄

Substituting Melanotan I for Melanotan II in prior research designs would not yield comparable data for any endpoint beyond basic melanogenesis. Melanotan II's effects on sexual behavior, appetite, and systemic melanocortin signaling depend on MC3R and MC4R activity that Melanotan I does not meaningfully engage. Any research protocol built around the multi-receptor pharmacology of Melanotan II would require complete redesign to account for Melanotan I's selective mechanism, and pigmentation outcomes would also differ in kinetics and delivery format.

Not sure which fits your research goals?

Use the Goal Finder

Answer 3 questions and get a personalised peptide recommendation ranked by evidence grade.

Find My Peptide →

More Comparisons

bpc 157 vs tb 500 mots c vs semaglutide dsip vs melanotan ii retatrutide vs tirzepatide cjc 1295 vs ipamorelin